Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide

Journal of Neurosurgery

Volumn 100, Issue 6, 2004, Pages 1060-1065

  Hirose, Yuicih ^a   Katayama, Makoto ^a   Berger, Mitchel S ^a   Pieper, Russell O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chk1; G2 arrest; p38; Temozolomide

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 7 HYDROXYSTAUROSPORINE; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 25C; CHECKPOINT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL STRAIN U87MG; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION; TUMOR CELL LINE;

EID: 2442689169     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2004.100.6.1060     Document Type: Article

References (21)

1. Bleehen NM, Newlands ES, Lee SM, et al: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913, 1995
2. Bunz F, Dutriaux A, Lengauer C, et al: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501, 1998
3. D'Atri S, Tentori L, Lacal PM, et al: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341, 1998
4. Denny BJ, Wheelhouse RT, Stevens MFG, et al: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045-9051, 1994
5. Goldmacher VS, Cuzick RA Jr, Thilly WG: Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N′-nitro-N-nitrosoguanidine. J Biol Chem 261:12462-12471, 1986
6. Gu Y, Rosenblatt J, Morgan DO: Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 11:3995-4005, 1992
7. Hirose Y, Berger MS, Pieper RO: Abrogation of the Chk1-mediated G2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61:5843-5849, 2001
8. Hirose Y, Berger MS, Pieper RO: p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957-1963, 2001
9. Hirose Y, Katayama M, Stokoe D, et al: The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 23:8306-8315, 2003
10. 6-methylguanione-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg 98:591-598, 2003
11. Kandel ES, Skeen J, Majewski N, et al: Activation of Akt/protein kinase B overcomes a G2/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22:7831-7841, 2002
12. Karran, P, Bignami M: Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res 20:2933-2940, 1992
13. 6-methylguanine residues in E. Coli DNA. Nature 296:868-869, 1982
14. Kat A, Thilly WG, Fang WH, et al: An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci 90:6424-6428, 1993
15. Nilsson I, Hoffman I: Cell cycle regulation by the cdc25 phosphatase family. Prog Cell Cycle Res 4:107-114, 2000
16. 2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501-1505, 1997
17. Prados MD: Future directions in the treatment of malignant gliomas with temozolomide. Semin Oncol (Suppl 6) 27:41-46, 2000
18. Sanchez Y, Wong C, Thoma RS, et al: Conservation of the chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through cdc25. Science 277:1497-1501, 1997
19. Sausville EA: Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies. Curr Med Chem Anti-Canc Agents 3:47-56, 2003
20. Senderowicz AM: Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther (Suppl 1) 2:S84-S95, 2003
21. Shtivelman E, Sussman J, Stokoe D: A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol 12:919-924, 2002